What is the share price of Kopran Ltd (KOPRAN) today?
The share price of KOPRAN as on 5th December 2025 is ₹137.11. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kopran Ltd (KOPRAN) share?
The past returns of Kopran Ltd (KOPRAN) share are- Past 1 week: 4.89%
- Past 1 month: -15.27%
- Past 3 months: -17.24%
- Past 6 months: -27.08%
- Past 1 year: -34.90%
- Past 3 years: -15.30%
- Past 5 years: 3.09%
What are the peers or stocks similar to Kopran Ltd (KOPRAN)?
The peers or stocks similar to Kopran Ltd (KOPRAN) include:What is the dividend yield % of Kopran Ltd (KOPRAN) share?
The current dividend yield of Kopran Ltd (KOPRAN) is 2.15.What is the market cap of Kopran Ltd (KOPRAN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kopran Ltd (KOPRAN) is ₹674.98 Cr as of 5th December 2025.What is the 52 week high and low of Kopran Ltd (KOPRAN) share?
The 52-week high of Kopran Ltd (KOPRAN) is ₹227.10 and the 52-week low is ₹123.11.What is the PE and PB ratio of Kopran Ltd (KOPRAN) stock?
The P/E (price-to-earnings) ratio of Kopran Ltd (KOPRAN) is 17.51. The P/B (price-to-book) ratio is 1.30.Which sector does Kopran Ltd (KOPRAN) belong to?
Kopran Ltd (KOPRAN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kopran Ltd (KOPRAN) shares?
You can directly buy Kopran Ltd (KOPRAN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kopran Ltd
KOPRAN Share Price
137.111.92% (-2.68)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
KOPRAN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KOPRAN Performance & Key Metrics
KOPRAN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 38.42 | 1.30 | 2.15% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
KOPRAN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
KOPRAN Company Profile
Kopran Limited is engaged in pharmaceutical business. The Company's business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
KOPRAN Sentiment Analysis
KOPRAN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
KOPRAN Stock Summary · March 2025
Kopran Limited is strategically merging with Kopran Laboratories to enhance its foothold in the burgeoning Indian diagnostic market, projected to reach $25 billion by FY '28. This merger, aimed at creating synergies and improving margins through efficient manufacturing of diagnostic kits, reflects management's optimism about future growth, particularly in the healthcare sector. Despite a strong year-over-year revenue increase, the company faces challenges in diversifying its revenue streams, heavily reliant on its clinical chemistry segment. Engaging actively with investors, management has addressed concerns regarding valuation while emphasizing a robust operational strategy focused on B2B opportunities in underserved markets. With plans for significant capital investment and a commitment to service delivery, Kopran is well-positioned to capitalize on the industry's projected growth of 14% to 15%.
KOPRAN Stock Growth Drivers
KOPRAN Stock Growth Drivers
6Merger and Synergies
Kopran Limited is in the process of merging with Kopran Laboratories, aiming to create synergies
Financial Performance and Growth
Kopran Laboratories reported a turnover of approximately INR 68-69 crores for the first nine months,
KOPRAN Stock Challenges
KOPRAN Stock Challenges
3Muted Revenue Performance
The company has reported muted revenue performance for the December period compared to the previous
Seasonality Concerns
There are concerns regarding the seasonality of the company's revenue, as the December period's performance
KOPRAN Forecast
KOPRAN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
KOPRAN
KOPRAN
Income
Balance Sheet
Cash Flow
Annual Normal View
KOPRAN Income Statement
KOPRAN Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 320.50 | 322.92 | 360.96 | 360.13 | 509.80 | 488.12 | 554.06 | 629.20 | 633.58 | 597.73 | ||||||||||
Raw Materials | 180.85 | 193.05 | 217.24 | 232.83 | 286.27 | 300.57 | 345.95 | 400.88 | 410.66 | 545.96 | ||||||||||
| Power & Fuel Cost | 13.71 | 14.90 | 17.10 | 18.08 | 16.65 | 19.27 | 23.16 | 24.52 | 26.45 | |||||||||||
| Employee Cost | 31.37 | 32.24 | 37.11 | 36.85 | 37.16 | 43.27 | 49.95 | 52.28 | 60.54 | |||||||||||
| Selling & Administrative Expenses | 25.39 | 28.17 | 27.88 | 29.60 | 34.24 | 35.75 | 35.37 | 37.00 | 39.15 | |||||||||||
| Operating & Other expenses | 22.39 | 14.56 | 12.24 | -4.00 | 35.71 | -8.73 | 44.77 | 25.50 | 19.91 | |||||||||||
EBITDA | 46.79 | 40.00 | 49.39 | 46.77 | 99.77 | 97.99 | 54.86 | 89.02 | 76.87 | 51.77 | ||||||||||
| Depreciation/Amortization | 8.33 | 8.51 | 8.74 | 9.58 | 10.19 | 11.10 | 12.71 | 12.89 | 15.59 | 16.41 | ||||||||||
| PBIT | 38.46 | 31.49 | 40.65 | 37.19 | 89.58 | 86.89 | 42.15 | 76.13 | 61.28 | 35.36 | ||||||||||
| Interest & Other Items | 13.70 | 8.60 | 8.99 | 8.91 | 6.24 | 5.12 | 6.08 | 8.59 | 9.34 | 9.56 | ||||||||||
| PBT | 24.76 | 22.89 | 31.66 | 28.28 | 83.34 | 81.77 | 36.07 | 67.54 | 51.94 | 25.80 | ||||||||||
| Taxes & Other Items | 4.85 | 2.40 | 7.64 | 7.27 | 21.73 | 20.75 | 8.83 | 16.59 | 13.39 | 8.23 | ||||||||||
| Net Income | 19.91 | 20.49 | 24.02 | 21.01 | 61.61 | 61.02 | 27.24 | 50.95 | 38.55 | 17.57 | ||||||||||
| EPS | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 13.34 | 5.65 | 10.57 | 7.99 | 3.64 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.22 | 0.53 | 0.28 | 0.38 | 0.82 |
KOPRAN Company Updates
FY 2026FY 2026
Investor Presentation
Nov 12PDF
Nov 12PDF
KOPRAN Stock Peers
KOPRAN Past Performance & Peer Comparison
KOPRAN Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kopran Ltd | 17.51 | 1.30 | 2.15% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
KOPRAN Stock Price Comparison
Compare KOPRAN with any stock or ETFCompare KOPRAN with any stock or ETF
KOPRAN
KOPRAN Holdings
KOPRAN Shareholdings
KOPRAN Promoter Holdings Trend
KOPRAN Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
KOPRAN Institutional Holdings Trend
KOPRAN Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 1.83%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KOPRAN Shareholding Pattern
KOPRAN Shareholding Pattern
KOPRAN Shareholding History
KOPRAN Shareholding History
Foreign Institutions
Mutual Funds Invested in KOPRAN
Mutual Funds Invested in KOPRAN
No mutual funds holding trends are available
Top 1 Mutual Funds holding Kopran Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0009% | Percentage of the fund’s portfolio invested in the stock 0.03% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 107/124 (-6) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing KOPRAN stock
smallcases containing KOPRAN stock
Looks like this stock is not in any smallcase yet.
KOPRAN Events
KOPRAN Events
KOPRAN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KOPRAN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 2.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹21.46 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KOPRAN Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KOPRAN has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 2.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹21.46 every year
KOPRAN Upcoming Dividends
KOPRAN Upcoming Dividends
No upcoming dividends are available
KOPRAN Past Dividends
KOPRAN Past Dividends
Cash Dividend
Ex DateEx DateSep 4, 2025
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 4, 2025
Cash Dividend
Ex DateEx DateSep 2, 2024
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 2, 2024
Cash Dividend
Ex DateEx DateSep 7, 2023
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 7, 2023
Cash Dividend
Ex DateEx DateAug 4, 2022
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Aug 4, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Aug 5, 2021
KOPRAN Stock News & Opinions
KOPRAN Stock News & Opinions
Articles & Videos
Earnings
Kopran reports consolidated net loss of Rs 9.92 crore in the September 2025 quarter
Net loss of Kopran reported to Rs 9.92 crore in the quarter ended September 2025 as against net profit of Rs 7.38 crore during the previous quarter ended September 2024. Sales declined 22.20% to Rs 117.91 crore in the quarter ended September 2025 as against Rs 151.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales117.91151.56 -22 OPM %-4.489.72 - PBDT-7.3413.50 PL PBT-11.639.64 PL NP-9.927.38 PL Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Kopran to conduct board meeting
Kopran will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Kopran Ltd Spurts 4.13%
Kopran Ltd gained 4.13% today to trade at Rs 163.7. The BSE Healthcare index is up 0.34% to quote at 44693.47. The index is down 0.96 % over last one month. Among the other constituents of the index, Aarti Pharmalabs Ltd increased 2.6% and Rainbow Childrens Medicare Ltd added 1.58% on the day. The BSE Healthcare index went up 7.92 % over last one year compared to the 1.11% surge in benchmark SENSEX. Kopran Ltd has lost 8.09% over last one month compared to 0.96% fall in BSE Healthcare index and 0.54% drop in the SENSEX. On the BSE, 25 shares were traded in the counter so far compared with average daily volumes of 20242 shares in the past one month. The stock hit a record high of Rs 369.2 on 09 Sep 2024. The stock hit a 52-week low of Rs 156.5 on 08 Aug 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Kopran to hold AGM
Kopran announced that the 66th Annual General Meeting(AGM) of the company will be held on 11 September 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Kopran consolidated net profit declines 32.88% in the June 2025 quarter
Net profit of Kopran declined 32.88% to Rs 7.45 crore in the quarter ended June 2025 as against Rs 11.10 crore during the previous quarter ended June 2024. Sales declined 3.03% to Rs 135.22 crore in the quarter ended June 2025 as against Rs 139.44 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales135.22139.44 -3 OPM %10.4513.02 - PBDT14.1518.61 -24 PBT9.8914.73 -33 NP7.4511.10 -33 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Kopran to table results
Kopran will hold a meeting of the Board of Directors of the Company on 29 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Kopran consolidated net profit declines 48.01% in the March 2025 quarter
Net profit of Kopran declined 48.01% to Rs 9.68 crore in the quarter ended March 2025 as against Rs 18.62 crore during the previous quarter ended March 2024. Sales declined 7.37% to Rs 172.36 crore in the quarter ended March 2025 as against Rs 186.08 crore during the previous quarter ended March 2024. For the full year,net profit declined 24.35% to Rs 38.55 crore in the year ended March 2025 as against Rs 50.96 crore during the previous year ended March 2024. Sales rose 2.44% to Rs 629.60 crore in the year ended March 2025 as against Rs 614.59 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales172.36186.08 -7 629.60614.59 2 OPM %9.9211.66 -11.5812.11 - PBDT17.5828.77 -39 67.5480.43 -16 PBT13.7125.18 -46 51.9567.54 -23 NP9.6818.62 -48 38.5550.96 -24 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Board of Kopran recommends final dividend
Kopran announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Kopran to hold board meeting
Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly
The United States Food and Drug Administration (USFDA) recently carried out a surveillance inspection at Kopran Research Laboratories, the company's wholly owned subsidiary. The inspection was conducted at the API manufacturing unit located in Mahad, Maharashtra, between April 21 and April 25, 2025. In a regulatory filing, Kopran confirmed that the inspection was concluded without any observations. Kopran is engaged in the business of manufacturing of formulation (finished dosage form). On a consolidated basis, net profit of Kopran declined 34.14% to Rs 10.40 crore while net sales rose 4.61% to Rs 166.24 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 11.96%, vs industry avg of 10.03%
Over the last 5 years, market share increased from 0.14% to 0.15%
Over the last 5 years, net income has grown at a yearly rate of 12.91%, vs industry avg of 20.02%